Affinity Asset Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Affinity Asset Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200,000	Closed	-$9.73M	–	103
2025 Q2	$9.73M	Buy	+200,000	New	+$7.74M	1.33%	25
2024 Q2	–	Sell	-65,000	Closed	-$4.43M	–	106
2024 Q1	$4.43M	Buy	+65,000	New	+$4.65M	0.55%	54
2022 Q3	–	Sell	-70,000	Closed	-$4.25M	–	68
2022 Q2	$4.25M	Buy	70,000 +15,000	+27%	+$882K	1.79%	22
2022 Q1	$3.45M	Buy	+55,000	New	+$3.45M	0.55%	29

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Affinity Asset Advisors's CRSP Position: Q1 2026 in Review

Affinity Asset Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 150,000 shares worth $7.14M. The stake represents 0.37% of the portfolio and ranks #60 among its holdings. This is a return to the name: Affinity Asset Advisors previously reported a position in CRSP as recently as Q4 2020.

Affinity Asset Advisors first reported a position in CRSP in Q4 2020 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Affinity Asset Advisors held 150,000 shares of CRISPR Therapeutics worth $7.14M as of Q1 2026.
CRISPR Therapeutics was a new Affinity Asset Advisors position in Q1 2026.
CRISPR Therapeutics made up 0.37% of Affinity Asset Advisors's portfolio in Q1 2026, its #60 holding.
Affinity Asset Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 2 quarters since.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.